JP2005516938A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005516938A5 JP2005516938A5 JP2003552781A JP2003552781A JP2005516938A5 JP 2005516938 A5 JP2005516938 A5 JP 2005516938A5 JP 2003552781 A JP2003552781 A JP 2003552781A JP 2003552781 A JP2003552781 A JP 2003552781A JP 2005516938 A5 JP2005516938 A5 JP 2005516938A5
- Authority
- JP
- Japan
- Prior art keywords
- agent
- compound
- cancer
- animal
- monosaccharide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003795 chemical substances by application Substances 0.000 claims 12
- 150000001875 compounds Chemical group 0.000 claims 10
- 201000011510 cancer Diseases 0.000 claims 6
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 6
- -1 hydroxy, carboxy Chemical group 0.000 claims 6
- 150000002772 monosaccharides Chemical class 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 229940088597 Hormone Drugs 0.000 claims 4
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 claims 4
- SRBFZHDQGSBBOR-SQOUGZDYSA-N Xylose Natural products O[C@@H]1CO[C@@H](O)[C@@H](O)[C@@H]1O SRBFZHDQGSBBOR-SQOUGZDYSA-N 0.000 claims 4
- 150000002016 disaccharides Chemical class 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 239000005556 hormone Substances 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 239000002246 antineoplastic agent Substances 0.000 claims 3
- 238000000315 cryotherapy Methods 0.000 claims 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 3
- 238000001415 gene therapy Methods 0.000 claims 3
- 229910052736 halogen Inorganic materials 0.000 claims 3
- 150000002367 halogens Chemical class 0.000 claims 3
- 239000002244 precipitate Substances 0.000 claims 3
- 229960000583 Acetic Acid Drugs 0.000 claims 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 2
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- FDDDEECHVMSUSB-UHFFFAOYSA-N Sulfanilamide Chemical group NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 claims 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-L Sulphite Chemical compound [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 claims 2
- 229960003487 Xylose Drugs 0.000 claims 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 2
- 150000001408 amides Chemical class 0.000 claims 2
- 150000001412 amines Chemical class 0.000 claims 2
- 150000001479 arabinose derivatives Chemical class 0.000 claims 2
- 125000004432 carbon atoms Chemical group C* 0.000 claims 2
- 230000001419 dependent Effects 0.000 claims 2
- 239000012362 glacial acetic acid Substances 0.000 claims 2
- 239000008103 glucose Substances 0.000 claims 2
- 230000003054 hormonal Effects 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 125000004435 hydrogen atoms Chemical class [H]* 0.000 claims 2
- 239000002955 immunomodulating agent Substances 0.000 claims 2
- 239000000376 reactant Substances 0.000 claims 2
- 229960001663 sulfanilamide Drugs 0.000 claims 2
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 2
- 150000003573 thiols Chemical class 0.000 claims 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims 2
- BZMHXOOEJJRVGM-UHFFFAOYSA-N 1,2-bis(1-methyl-2,3-dihydroindol-2-yl)ethane-1,2-dione Chemical compound C1C2=CC=CC=C2N(C)C1C(=O)C(=O)C1N(C)C2=CC=CC=C2C1 BZMHXOOEJJRVGM-UHFFFAOYSA-N 0.000 claims 1
- JHFAEUICJHBVHB-UHFFFAOYSA-N 1H-indol-2-ol Chemical compound C1=CC=C2NC(O)=CC2=C1 JHFAEUICJHBVHB-UHFFFAOYSA-N 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000010438 heat treatment Methods 0.000 claims 1
- 238000001794 hormone therapy Methods 0.000 claims 1
- 238000009169 immunotherapy Methods 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 238000001308 synthesis method Methods 0.000 claims 1
- 230000002194 synthesizing Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Claims (17)
- R1またはR2が、アセチル化したアラビノース、グルコース、マンノース、リボース、またはキシロースである、請求項1記載の化合物。
- 治療学的に有効量の式Iの化合物と医薬として許容されうるキャリヤーとを含む、動物における癌を治療するための医薬組成物。
- 放射線治療剤、ホルモン治療剤、免疫治療剤、化学治療剤、凍結治療剤、および遺伝子治療剤からなる群から選択されるさらなる薬剤を含む、請求項1記載の医薬組成物。
- 前記化合物が経口投与用に製剤される、請求項1記載の医薬組成物。
- 治療学的に有効量の請求項4記載の医薬組成物を動物に投与することを含む、癌の治療法。
- 前記動物がヒトであり、前記化合物を、放射線治療剤、ホルモン治療剤、免疫治療剤、化学治療剤、凍結治療剤、および遺伝子治療剤からなる群から選択されるさらなる薬剤と組み合わせて投与する、請求項7記載の治療法。
- ほぼ等モル量の2−ヒドロキシインドールとN−メチルインドリニル−ジケトンを合わせて反応物質を得ること;
前記反応物質と過剰量の氷酢酸とを混合して混合物を作製すること;
前記混合物を約70〜80℃で1〜3時間加熱して沈殿物を形成させること;および
前記沈殿物をメイソインジゴ化合物として回収すること;
を含む、メイソインジゴ化合物の合成法。 - 前記沈殿物を、少なくとも氷酢酸、水、またはエタノールで洗浄する、請求項9記載の合成法。
- 式(I)、(II)、または(III)
- R1またはR2が、アセチル化したアラビノース、グルコース、マンノース、リボース、またはキシロースである、請求項11記載の治療法。
- 前記動物がヒトであり、前記医薬組成物を経口投与する、請求項11記載の治療法。
- 前記化合物を、放射線治療剤、ホルモン治療剤、免疫治療剤、化学治療剤、凍結治療剤、および遺伝子治療剤からなる群から選択されるさらなる薬剤と組み合わせて投与する、請求項11記載の治療法。
- 治療しようとする前記固形腫瘍癌が、結腸癌、ホルモン依存性もしくはホルモン非依存性の前立腺癌、乳癌、または肺癌である、請求項11記載の治療法。
- 前記固形腫瘍癌がホルモン依存性もしくはホルモン非依存性の前立腺癌である、請求項11記載の治療法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/021,589 US6566341B1 (en) | 2001-12-13 | 2001-12-13 | Derivative of isoindigo, indigo and indirubin for the treatment of cancer |
US40726702P | 2002-09-03 | 2002-09-03 | |
PCT/US2002/039866 WO2003051900A1 (en) | 2001-12-13 | 2002-12-13 | Derivatives of isoindigo, indigo and indirubin and use in treating cancer |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2005516938A JP2005516938A (ja) | 2005-06-09 |
JP2005516938A5 true JP2005516938A5 (ja) | 2005-12-22 |
Family
ID=26694875
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2003552781A Pending JP2005516938A (ja) | 2001-12-13 | 2002-12-13 | イソインジゴ、インジゴおよびインジルビンの誘導体、ならびに癌治療における使用 |
Country Status (8)
Country | Link |
---|---|
US (1) | US6933315B2 (ja) |
EP (1) | EP1458734B1 (ja) |
JP (1) | JP2005516938A (ja) |
AT (1) | ATE484514T1 (ja) |
AU (1) | AU2002357191A1 (ja) |
CA (1) | CA2469649C (ja) |
DE (1) | DE60237993D1 (ja) |
WO (1) | WO2003051900A1 (ja) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8563525B2 (en) | 2004-01-12 | 2013-10-22 | Natrogen Therapeutics International, Inc. | Methods of treating an inflammatory-related disease |
US8748475B2 (en) | 2004-01-12 | 2014-06-10 | Natrogen Therapeutics International, Inc. | Methods and compositions for treating lupus |
US20100098702A1 (en) | 2008-09-16 | 2010-04-22 | Longgui Wang | Method of treating androgen independent prostate cancer |
US7582670B2 (en) | 2001-12-13 | 2009-09-01 | Natrogen Therapeutics, Inc. | Methods of treating an inflammatory-related disease |
US20050154046A1 (en) * | 2004-01-12 | 2005-07-14 | Longgui Wang | Methods of treating an inflammatory-related disease |
CN101074229B (zh) * | 2007-06-08 | 2010-09-01 | 无锡杰西医药科技有限公司 | 7-氮杂靛玉红和7-氮杂异靛蓝衍生物制备及其药学用途 |
CN101426268B (zh) * | 2007-11-02 | 2010-08-25 | 大唐移动通信设备有限公司 | 导频资源分配方法、系统和设备 |
US8563595B2 (en) * | 2008-11-14 | 2013-10-22 | Board Of Regents, The University Of Texas System | Treatment of cancer with complex organic-inorganic pigment compositions |
WO2013142817A2 (en) * | 2012-03-23 | 2013-09-26 | Dennis Brown | Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo |
EP2863897B1 (en) * | 2012-06-21 | 2019-06-19 | Phosphorex Inc. | Nanoparticles of indirubin, derivatives thereof and methods of making and using same |
CN103333161B (zh) * | 2013-05-28 | 2015-09-30 | 滁州市洛达生物科技有限公司 | 1’-氧代靛玉红的制备和用途 |
US11510915B2 (en) * | 2017-05-26 | 2022-11-29 | Taiho Pharmaceutical Co., Ltd. | Anti-tumor effect potentiator using novel biphenyl compound |
CN110740991B (zh) | 2017-05-26 | 2023-07-04 | 大鹏药品工业株式会社 | 新型联苯化合物或其盐 |
US20220009889A1 (en) * | 2018-12-07 | 2022-01-13 | Natrogen Therapeutics International, Inc. | Polymorphic form of meisoindigo and modified formulation of meisoindigo |
US11345818B1 (en) | 2020-12-29 | 2022-05-31 | Industrial Technology Research Institute | Dye for fiber and dyeing method |
WO2022232243A1 (en) * | 2021-04-27 | 2022-11-03 | Curapep Llc | Compositions for wound relief and inhibiting a phd protein and methods of treatment |
CN114920728B (zh) * | 2022-05-27 | 2023-10-20 | 中南大学 | 一种甲异靛衍生物及其制备方法与应用 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS617254A (ja) * | 1984-06-20 | 1986-01-13 | Isukura Sangyo Kk | ビスインドリノンおよびそれを主成分とする制癌剤 |
US5696092A (en) * | 1995-03-07 | 1997-12-09 | George Washington University | Methods and compositions for inhibiting metastasis of epithelial cell-derived cancers |
JP2002516851A (ja) * | 1998-05-29 | 2002-06-11 | ゲルハルト アイゼンブランド | サイクリン依存性キナーゼを阻害する医薬製造のためのインジゴイドビスインドール誘導体の使用 |
CN1378447A (zh) * | 1999-04-12 | 2002-11-06 | 海恩兹·赫伯特·菲比格 | 穿透细胞膜的靛类双吲哚衍生物的用途 |
KR20010112424A (ko) * | 1999-04-12 | 2001-12-20 | 아이젠 브란트 게르하르트 | 인디고이드 비스인돌 유도체 |
-
2002
- 2002-12-13 AT AT02805123T patent/ATE484514T1/de not_active IP Right Cessation
- 2002-12-13 EP EP02805123A patent/EP1458734B1/en not_active Expired - Lifetime
- 2002-12-13 CA CA2469649A patent/CA2469649C/en not_active Expired - Lifetime
- 2002-12-13 AU AU2002357191A patent/AU2002357191A1/en not_active Abandoned
- 2002-12-13 WO PCT/US2002/039866 patent/WO2003051900A1/en active Search and Examination
- 2002-12-13 JP JP2003552781A patent/JP2005516938A/ja active Pending
- 2002-12-13 DE DE60237993T patent/DE60237993D1/de not_active Expired - Lifetime
-
2004
- 2004-06-10 US US10/864,458 patent/US6933315B2/en not_active Expired - Lifetime
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2005516938A5 (ja) | ||
EP2393827B1 (en) | Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens | |
US10975089B2 (en) | Radiopharmaceuticals, radioimaging agents, and uses thereof | |
US9365510B2 (en) | Aziridine bisphenol ethers and related compounds and methods for their use | |
CA2469649A1 (en) | Derivatives of isoindigo, indigo and indirubin and use in treating cancer | |
EP2268604B1 (en) | Therapies for cancer using isotopically substituted lysine | |
HUT59370A (en) | Chelating agents for complex formation with radioactive isotopes, their metal complexes and the use thereof for diagnostic and therapeutic purposes | |
US9125946B2 (en) | Halogenated phenols for diagnostics, antioxidant protection and drug delivery | |
WO2018045450A1 (en) | Bisphenol a compounds and methods for treating drug-resistant androgen receptor mediated cancers | |
EP3148970B1 (en) | Androgen receptor modulators and methods for their use | |
TW593328B (en) | Proactive antitumor compounds | |
CN1122132A (zh) | 配位体及其金属配合物 | |
CN114702544B (zh) | 一种氨基甾体化合物及其制备方法和应用 | |
CN104974252B (zh) | 一种抑制肿瘤生长的抗体-小分子药物偶联物及其制备方法和用途 | |
CN114349807B (zh) | 一种唾液酸连接吲哚菁绿Sia-ICG及其制备方法和应用 | |
CN101289421A (zh) | 烟酰氨基酸类化合物的合成方法及其对肿瘤放疗的增敏作用 | |
JPS5874641A (ja) | デカルボキシラ−ゼを阻害するフツ素化アルカンジアミン誘導体 | |
JPS62152B2 (ja) | ||
US10220100B2 (en) | Halogenated phenols for diagnostics, antioxidant protection and drug delivery | |
WO1990000557A1 (en) | 5-substituted uridine derivatives and intermediates for their preparation | |
JP3718533B2 (ja) | ジヒドロキシフェニルスルフィド誘導体またはその塩を含む抗メラノーマ剤 | |
JP2003160564A (ja) | アルカンスルホニルピリジンの製造方法 | |
JP2004534079A (ja) | 抗腫瘍アントラサイクリングリコシド14−スルホン酸誘導体 | |
JP2005532310A5 (ja) |